Cancer Biology & Medicine

Papers
(The TQCC of Cancer Biology & Medicine is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Breast cancer incidence and mortality in women in China: temporal trends and projections to 203083
Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants82
Current cancer burden in China: epidemiology, etiology, and prevention61
Stimuli-responsive nanocarriers for therapeutic applications in cancer41
Predictive value of MGMT promoter methylation on the survival of TMZ treated <i>IDH</i>-mutant glioblastoma28
Tumorigenic bacteria in colorectal cancer: mechanisms and treatments26
Exosome-mediated cellular crosstalk within the tumor microenvironment upon irradiation24
Competing endogenous RNAs in lung cancer24
Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data22
Circular RNAs: new biomarkers of chemoresistance in cancer21
Nanotechnology assisted photo- and sonodynamic therapy for overcoming drug resistance21
Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer21
Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development20
Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas19
The role and its mechanism of intermittent fasting in tumors: friend or foe?19
The IL-33/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization19
Breast cancer screening and early diagnosis in Chinese women18
Gold-based nanomaterials for the treatment of brain cancer18
Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity17
Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA17
The advanced development of molecular targeted therapy for hepatocellular carcinoma17
Recent progress of nanotechnology-based theranostic systems in cancer treatments17
Morphine-3-glucuronide upregulates PD-L1 expression <i>via</i> TLR4 and promotes the immune escape of non-small cell lung cancer17
BYSL contributes to tumor growth by cooperating with the mTORC2 complex in gliomas16
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer16
Biological roles and potential clinical values of circular RNAs in gastrointestinal malignancies16
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases16
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors16
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells15
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial15
Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies15
Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas15
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer <i>in vivo</i>14
Bacterial outer membrane vesicle-based cancer nanovaccines14
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events14
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification14
Advances in lung cancer screening and early detection14
NEDD9 promotes cancer stemness by recruiting myeloidderived suppressor cells <i>via</i> CXCL8 in esophageal squamous cell carcinoma13
Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer13
Methods for monitoring cancer cell pyroptosis13
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study13
VEGFR2 inhibition hampers breast cancer cell proliferation <i>via</i> enhanced mitochondrial biogenesis13
Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion13
Major roles of the circadian clock in cancer12
Targeting myeloid-derived suppressor cells for cancer therapy12
Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives12
Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies11
Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids11
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer11
Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study11
Personalized immunotherapy in cancer precision medicine10
LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA10
L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma10
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy10
Targeting PP2A for cancer therapeutic modulation10
Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials10
Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma10
Updating targets for natural killer/T-cell lymphoma immunotherapy10
The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma10
The m6A writers regulated by the IL-6/STAT3 inflammatory pathway facilitate cancer cell stemness in cholangiocarcinoma9
Exosomal miR-155 from gastric cancer induces cancer-associated cachexia by suppressing adipogenesis and promoting brown adipose differentiation via C/EPBβ9
Immunology and immunotherapy in breast cancer9
Modulating microRNAs in cancer: Next-generation therapies9
The advance of adjuvant treatment for triple-negative breast cancer9
Living biobank-based cancer organoids: prospects and challenges in cancer research9
PGK1-coupled HSP90 stabilizes GSK3β expression to regulate the stemness of breast cancer stem cells9
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi8
A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cance8
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms8
Cancer immunology and immunotherapy8
Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies8
CD13 inhibition augments DR4-induced tumor cell death in a p-ERK1/2-independent manner8
Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling8
Akt isoforms differentially provide for chemoresistance in prostate cancer7
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma7
LncRNA DPP10-AS1 promotes malignant processes through epigenetically activating its cognate gene DPP10 and predicts poor prognosis in lung cancer patients7
The cancer-testis gene, <i>MEIOB</i>, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency7
Effects of population aging on the mortality burden of related cancers in urban and rural areas of China, 2004–2017: a population-based study7
SNORA23 inhibits HCC tumorigenesis by impairing the 2'-O-ribose methylation level of 28S rRNA7
The biogenesis, function and clinical significance of circular RNAs in breast cancer7
Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy7
Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment6
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP6
Single-cell trajectories of melanoma cell resistance to targeted treatment6
Epithelial-mesenchymal transition-related circular RNAs in lung carcinoma6
N6-methyladenosine (m6A) RNA modification in tumor immunity6
A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma6
Targeting the COP9 signalosome for cancer therapy6
Prospective study of the effect of ERAS on postoperative recovery and complications in patients with gastric cancer6
sLe<sup>x</sup> expression in invasive micropapillary breast carcinoma is associated with poor prognosis and can be combined with MUC1/EMA as a supplementary diagnostic indicator6
Circular RNAs: implications of signaling pathways and bioinformatics in human cancer6
Analysis of the <i>HNF4A</i> isoform-regulated transcriptome identifies CCL15 as a downstream target in gastric carcinogenesis6
Is adjuvant chemotherapy necessary for early gastric cancer?6
SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer6
A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer6
The Wnt/β-catenin signaling pathway in the tumor microenvironment of hepatocellular carcinoma6
0.037497043609619